PerkinElmer
check quantity

CXCL1/GROα (human) AlphaLISA Detection Kit, 500 assay points

The AlphaLISA® Human CXCL1/GROα Detection Kit is designed for detection and quantitation of human CXCL1/GROα in cell culture media or serum using a homogeneous (no-wash steps, no separation steps) assay.

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Part Number
Unit Size
List Price
Your Price
Quantity
AL349C
500 assay points
1811.00 USD
 
more
AL349F
5,000 assay points
12000.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Formats:

  • Our HV (100 assay point) kits allow you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample).
  • Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).
  • Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample).

Features:

  • No-wash steps, no separation steps
  • ELISA alternative technology
  • Sensitive detection
  • Broad sample compatibility
  • Small sample volume
  • Results in less than 3 hours
  • Half the time of an ELISA assay

C-X-C Motif Chemokine 1 (CXCL1) is an 11 kDa chemokine and is part of the intercrine alpha (chemokine CXC) family. The secreted protein is proteolytically processed at the N-terminus and the processed form is usually referred to as GRO-α. CXCL1 is expressed by macrophages, neutrophils and epithelial cells. Its synthesis is induced by a variety of inflammatory mediators such as PDGF, M-CSF, TNFα, LPS, and TLR 4. The major role of CXCL1 is its chemoacttractant activity on neutrophils. CXCL1 plays a role in inflammation and exerts its effects on endothelial cells in an autocrine way. CXCL1 is implicated in spinal cord development, angiogenesis, inflammation, wound healing, and tumorigenesis. CXCL1 is overexpressed in invasive bladder cancer and is secreted by human melanoma cells.

AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.

Specifications

Assay Target CXCL1/GROα
Assay Target Class Cytokine
Automation Compatible Yes
Detection Method Alpha
Experimental Type In vitro
Product Brand Name AlphaLISA
Shipping Condition Blue Ice
Therapeutic Area Inflammation
Unit Size 500 assay points
Resources, Events & More
  • All

Application Brief

Eight Limitations of ELISA and How to Overcome Them Using Alternative Technologies

The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.

Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.

PDF 1 MB

Application Note

Effects of 5FU and Sorafenib on Proliferation and Biomarker Expression in a Colorectal Cancer Model Using AlphaLISA and EnSight Solutions

A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.

In this application note you will learn:

  • How to rapidly measure multiple biomarkers in both cell culture supernatant and lysates from the same wells of a microplate to examine complex protein expression profiles from a colorectal cancer cellular model
  • Benefits of using AlphaLISA® technology for characterizing the effects of potential drugs with different modes of action on a cell culture model of human colorectal cancer
  • How to measure the effects of drug treatments, such as 5FU and Sorafenib, on cellular proliferation by automated well-imaging and cell counting using the EnSight® multimode plate reader
  • Examples of the data and analysis you can generate for such biomarker and proliferation assays

PDF 3 MB
Using AlphaLISA Biomarker Kits to Assess Effects of PBMC-Conditioned Media on 3D and 2D Cell Culture Models of Breast Cancer

Various cytokines are secreted during an active immune response that can have modulatory effects on target cell populations, including interferon gamma (IFN-ɣ), tumor necrosis factor alpha (TNFa) and several interleukins.

In this application note, you will learn how we investigated:

  • The effects of secreted factors on a triple-negative breast cancer cell line by treatment with conditioned media from activated PBMCs
  • Whether the modulatory effects of cytokines secreted by infiltrating immune is different when studied in 3D cell cultures
  • How to detect and quantify multiple immune-modulated proteins from the same wells in complex cell models grown in 3D spheroid microplates and traditional 2D cell culture using AlphaLISA® technology and EnVision® multimode plate reader in a workflow with ATPlite 1step and Opera® Phenix high-content screening system

PDF 2 MB

Brochure